Jump to content

Covid-19: Razvoj vakcine, imunitet i primena medikamenata

Featured Replies

Quote

 

Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.
...
The timeline would make the vaccine one of the fastest-moving in the world. Some analysts expect a vaccine to be approved for use by November in the U.S., a move which may give President Donald Trump a new foothold in the election.

Pfizer and BioNTech last month clinched a $2 billion deal to supply an initial 100 million doses of the vaccine to the U.S. Governments around the world are looking to lock up supplies of still-experimental candidates in hope of stabilizing local economies and stopping spread of the virus that’s taken almost 800,000 lives globally.

 

https://www.bloomberg.com/news/articles/2020-08-21/pfizer-virus-vaccine-on-track-for-regulatory-review-in-october?srnd=premium

Quote

 

Johnson & Johnson (JNJ.N) aims to test its experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.

The trial would be conducted in nearly 180 sites across the United States and other countries, including Brazil and Mexico, according to the information posted on clinicaltrials.gov on Aug. 10.

“We can confirm that planning and recruitment is underway for our Phase 3 program, which is subject to interim data of the Phase 1/2a trials and approval of regulators,” a Johnson & Johnson spokesman said.

“Our Phase 3 program is intended to be as robust as possible, could include up to 60,000 participants and will be conducted in places with high incidence rates,” he added.

The spokesman said J&J is using epidemiological data to decide where studies should take place and will make a final decision soon. The phase 3 trial will likely lock off in late September, with the first vaccines available for use by early 2021, he said.

 

https://www.reuters.com/article/us-health-coronavirus-johnson-johnson/johnson-johnson-to-test-coronavirus-vaccine-in-60000-volunteers-idUSKBN25G1WU

Edited by vememah

Self-cleaning mask can kill viruses with heat from phone charger, researchers say
 
Israeli researchers say they have invented a reusable face mask that can kill the coronavirus with heat by drawing power from a mobile phone charger.
 
The disinfecting process takes about 30 minutes - and users should not wear the mask while it is plugged in, said Professor Yair Ein-Eli, who led the research team at Technion University in Haifa.
 
Professor Allon Moses, an infectious diseases expert at Jerusalem’s Hadassah Medical Center, said there was “no question” that a half hour’s exposure to 70-degree heat would kill the coronavirus.
 
 

But he cautioned that repeated heating could “damage the mask’s paper or fabric and spoil its ability to protect from diseases in the future”.

During testing, the prototype was exposed to 20 heating cycles, each for half an hour, with no impact on durability, Ein-Eli said.

“We can guarantee it up to a few dozen cycles, without any risk,” he added.

The researchers submitted a patent for the mask in the United States in late March and say they are discussing commercializing the product with the private sector.

It will likely sell at a $1 premium over the price of a typical disposable face mask, the researchers say.

 
 

De si cedo.
Izraelci su javljali još u martu da samo što nisu napravili vakcinu. Just sayin

Kilo soli dnevno i resen problem :fantom:

...

Edited by vememah

2 hours ago, Dankan Ajdaho said:

 

Researchgate je "social networking website for academia". Prema Wikipediji, da bi se registrovao, potrebno je da imaš email adresu na nekoj "instituciji". Autor ovog članka, prema njegovom profilu na LinkedInu je Chief Research Scientist at SAIC. Ima PhD iz fizike. Sa sajta SAIC-a, šta rade: 

 

Koliko vidim iz apstrakta rada i letimičnog prelaženja samog rada, ovo nije originalan naučni rad zasnovan na originalnom istraživanju. Ovo je, kako sam autor kaže u apstraktu: "This paper summarizes this all [razne preporuke za uzimanje joda] and suggests grassroots action." Dakle, njegova sinteza raznih radova i preporuka koje je pročitao i njegov lični predlog za akciju.

 

Ovaj "rad" je samo tekst nekog čoveka koji radi za neku firmu koji je objavio na social(professional) networking sajtu. I to bi bilo to.

 

To što je B92 ovo preneo je, s oproštenjem, fake news.

 

Screenshot 2020-08-22 at 15.59.34.png

Edited by trustno1

Nije ni samo b92. Čitala sam, na primer, da je došlo do poplave naučnih radova u vezi sa kovidom i da su i neki prestižni naučni časopisi objavili djubre. Osim toga, namerni i slučajni gluvi telefoni nisu novost. Poznati primer: naučnici našli da kovid antitela kod nekih pacijenata nestaju posle nekoliko meseci. Vest: dokazano se gubi imunitet posle tri meseca. Istina: nije dokazano. Imunitet nisu samo antitela već i t-cells, itd. Da ne spominjem informacije od pre DKT o slabljenju virusa na koje su se upecali i neki ovde na forumu.

I zato je stvarno baš važno pitanje gde se snabdevaš informacijama. Pročitala sam savet jednog naučnika: odaberi oko 3 stručna izvora kojima veruješ i to je to. A i to moraš pažljivo da čitaš koristeći sve svoje moći rasudjivanja. :)

Pa to je to.

 

S tim što živim da će od tih par miliona baram par stotina hiljada botova odavde biti predstavljeni kao dobrovoljci za primanje ruske vakcine. Ili bilo koje druge.

Sada su prvi put zvanično ustanovili da je jedan bivši pozitivni opet pozitivan. Prvi put je imao lagane simptome a sada je bez simptoma. Zarazen sa dva razlicita soja virusa. 

koliko je vremena proslo izmedju? 

4,5 mjeseca. Ovo se desilo u Hong Kongu

sacekajmo vise informacija i analize sta se desilo i da li je to moguce da se ponovi.